Compare METC & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | METC | OCS |
|---|---|---|
| Founded | 2015 | 2003 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Coal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 790.3M | 732.4M |
| IPO Year | 2016 | 2022 |
| Metric | METC | OCS |
|---|---|---|
| Price | $14.01 | $12.18 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 6 |
| Target Price | $34.00 | ★ $42.00 |
| AVG Volume (30 Days) | ★ 2.3M | 185.6K |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $19.61 | $466.06 |
| Revenue Next Year | $11.96 | $479.73 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.56 | $10.52 |
| 52 Week High | $57.80 | $34.48 |
| Indicator | METC | OCS |
|---|---|---|
| Relative Strength Index (RSI) | 62.51 | 40.78 |
| Support Level | $13.35 | $10.63 |
| Resistance Level | $16.20 | $13.49 |
| Average True Range (ATR) | 0.97 | 0.44 |
| MACD | 0.34 | -0.07 |
| Stochastic Oscillator | 82.02 | 12.28 |
Ramaco Resources Inc is a United States-based company that operates as a pure-play metallurgical coal company with operations in southern West Virginia and southwestern Virginia. Its portfolio includes high-quality metallurgical coal reserves & resources, with a focus on properties such as Elk Creek, Berwind, Knox Creek, and Maben. These properties are strategically located to serve North American blast furnace steel mills and coke plants, as well as international metallurgical coal consumers. Additionally, the company controls mineral deposits in Sheridan, Wyoming, exploring potential opportunities in rare earth elements and coal-to-carbon-based products. The company's two operating segments are Metallurgical Coal segment; and Rare Earths and Critical Minerals.
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company has locations in five countries: Switzerland, Iceland, France, U.S. and Hong Kong.